Concord Deferred Long Term Liab from 2010 to 2024

CCM Stock  USD 7.73  0.27  3.37%   
Concord Medical Deferred Long Term Liabilities yearly trend continues to be very stable with very little volatility. Deferred Long Term Liabilities is likely to drop to about 1.5 M. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2010-12-31
Previous Quarter
M
Current Value
1.5 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Concord Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Concord Medical's main balance sheet or income statement drivers, such as Interest Expense of 174 M, Selling General Administrative of 190.2 M or Total Revenue of 458 M, as well as many indicators such as Price To Sales Ratio of 0.63, Dividend Yield of 0.12 or Days Sales Outstanding of 47.42. Concord financial statements analysis is a perfect complement when working with Concord Medical Valuation or Volatility modules.
  
Check out the analysis of Concord Medical Correlation against competitors.

Latest Concord Medical's Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of Concord Medical Services over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Concord Medical's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Concord Medical's overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

Concord Deferred Long Term Liab Regression Statistics

Arithmetic Mean1,362,173
Geometric Mean884,886
Coefficient Of Variation77.30
Mean Deviation729,503
Median1,120,000
Standard Deviation1,052,973
Sample Variance1.1T
Range4.5M
R-Value0.32
Mean Square Error1.1T
R-Squared0.10
Significance0.25
Slope74,746
Total Sum of Squares15.5T

Concord Deferred Long Term Liab History

20241.5 M
2023M
20191.8 M
2018267 K
20171.1 M
20161.1 M
20154.5 M

About Concord Medical Financial Statements

Concord Medical investors utilize fundamental indicators, such as Deferred Long Term Liab, to predict how Concord Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Deferred Long Term LiabilitiesM1.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Concord Medical Services is a strong investment it is important to analyze Concord Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Concord Medical's future performance. For an informed investment choice regarding Concord Stock, refer to the following important reports:
Check out the analysis of Concord Medical Correlation against competitors.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.18)
Revenue Per Share
107.978
Quarterly Revenue Growth
(0.23)
Return On Assets
(0.04)
Return On Equity
(0.32)
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.